Viatris (VTRS) Valuation Check After First International Inpefa Heart Failure Launch [Yahoo! Finance]
Viatris Inc. (VTRS)
Company Research
Source: Yahoo! Finance
Viatris (VTRS) is back in focus after the company launched its heart failure treatment Inpefa in the United Arab Emirates, marking its first commercialization of the drug outside the U.S. and Europe. See our latest analysis for Viatris. The Inpefa launch lands at a time when momentum in Viatris' share price has been building, with a 30 day share price return of 7.92% and a 90 day share price return of 27.63%. The 1 year total shareholder return sits at 23.94%, compared with a weaker 5 year total shareholder return of 4.88%. If this heart failure launch has you thinking more broadly about healthcare opportunities, it could be worth scanning healthcare stocks as a way to spot other potential ideas in the sector. With Viatris trading at US$13.21, a value score of 5, a very large intrinsic discount estimate of 73%, and a recent share price surge, the key question is whether there is still an opportunity for investors to consider or if the market is already pricing in future growt
Show less
Read more
Impact Snapshot
Event Time:
VTRS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VTRS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VTRS alerts
High impacting Viatris Inc. news events
Weekly update
A roundup of the hottest topics
VTRS
News
- Davis Opportunity Fund Annual Review 2026 [Seeking Alpha]Seeking Alpha
- Is Viatris (VTRS) Pricing Reflect Its Recent Multi-Year Share Price Recovery [Yahoo! Finance]Yahoo! Finance
- Viatris Earnings Preview: What to Expect [Yahoo! Finance]Yahoo! Finance
- 3 Reasons to Sell VTRS and 1 Stock to Buy Instead [Yahoo! Finance]Yahoo! Finance
- Viatris Expands Innovative Portfolio in Cardiovascular Diseases with the Company's First Launch of Inpefa® (Sotagliflozin) for the Treatment of Heart Failure [Yahoo! Finance]Yahoo! Finance
VTRS
Earnings
- 11/6/25 - Beat
VTRS
Sec Filings
- 1/2/26 - Form 4
- 12/8/25 - Form 8-K
- 12/5/25 - Form 8-K
- VTRS's page on the SEC website